Premium
Treatment of high‐risk patients with subvesical obstruction from advanced prostatic carcinoma using a thermosensitive mesh stent
Author(s) -
GOTTFRIED H.W.,
GNANN R.,
BRÄNDLE E.,
BACHOR R.,
GSCHWEND J.E.,
KLEINSCHMIDT K.
Publication year - 1997
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1997.00416.x
Subject(s) - stent , medicine , carcinoma , urology , oncology , radiology
Objective To evaluate the results obtained using a permanent prostatic stent system (Memotherm ® , Bard/Angiomed, Karlsruhe, Germany) in high‐risk patients with advanced prostatic carcinoma and subvesical obstruction. Patients and methods The study included 35 patients (mean age 75.3 years, range 53–89) with advanced prostatic carcinoma and persistent subvesical obstruction despite androgen ablation. Because of serious concurrent diseases, 49% of these patients were classified as American Society of Anesthesiologists (ASA) grade 3 and 51% as ASA grade 4. The patients were treated using the Memotherm ® stent, a thermosensitive Nitinol TM mesh stent. The outcome was assessed by measuring voiding variables, a symptom score and as the incidence of complications. Results After inserting the stent, 33 (94%) of the patients were able to void spontaneously and there was a statistically significant improvement in the voiding variables. These results remained unchanged over a mean (range) follow‐up of 15.2 months (3–38). There were no serious complications arising from the insertion of the stent. Conclusion For high‐risk patients with subvesical obstruction caused by prostatic carcinoma, the insertion of a permanent metal stent system offers a useful alternative treatment to transurethral resection.